AAA
MNPR icon

Affinity Asset Advisors’s Monopar Therapeutics MNPR Stock Holding History

Affinity Asset Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-79,483
Closed -$6.49M – 109
2025
Q3 		$6.49M Buy
79,483
+11,983
+18% +$536K 0.57% 46
2025
Q2 		$2.42M Buy
67,500
+5,500
+9% +$200K 0.33% 52
2025
Q1 		$2.26M Buy
+62,000
New +$2.23M 0.22% 63

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Affinity Asset Advisors's MNPR Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Monopar Therapeutics (MNPR) in Q4 2025, closing a stake of 79,483 shares — an estimated $6.49M sold.

Affinity Asset Advisors first reported a position in MNPR in Q1 2025 and held it in 3 quarters. The position peaked at $6.49M in Q3 2025. 74 funds tracked by Wall St. Rank hold MNPR as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Monopar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 79,483 Monopar Therapeutics shares in Q4 2025, an estimated $6.49M.
  • Affinity Asset Advisors first reported a position in Monopar Therapeutics in Q1 2025 and held it in 3 quarters.
  • Affinity Asset Advisors's Monopar Therapeutics position peaked at $6.49M in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.